ArticleClinical sarcoma research2019

Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.

Jerry W Call et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.